key: cord-1051619-1jnia8ja
authors: Aziz, Faisal; Behrendt, Christian-Alexander; Sullivan, Kaity; Beck, Adam W; Beiles, C Barry; Boyle, Jon R; Mani, Kevin; Benson, Ruth A; Wohlauer, Max V; Khashram, Manar; Jorgensen, Jens Eldrup; Lemmon, Gary W
title: The Impact of COVID-19 Pandemic on Vascular Registries and Clinical Trials
date: 2021-05-21
journal: Semin Vasc Surg
DOI: 10.1053/j.semvascsurg.2021.04.001
sha: 0c69604ec40cad3efbe659fc0a4a144954db516c
doc_id: 1051619
cord_uid: 1jnia8ja

Quality improvement programs and clinical trial research experienced disruption due to the COVID-19 pandemic. Vascular registries showed an immediate impact with significant declines in second quarter vascular procedure volumes witnessed across Europe and the United States. To better understand the magnitude and impact of the pandemic, organizations and study groups sent grass roots surveys to vascular specialists for needs assessment. Several vascular registries responded quickly by insertion of COVID-19 variables into their data collection forms. Over 80% of clinical trials have been reported delayed or not started due to factors that included loss of enrollment from patient concerns or mandated institutional shutdowns, weighing the risk of trial participation on patient safety. Preliminary data of patients undergoing vascular surgery with active COVID-19 infection shows inferior outcomes (morbidity) and increased mortality. Disease specific vascular surgery study collaboratives about COVID-19 were created for the desire to study the disease in a more focused manner than possible through registry outcomes. This review describes the pandemic effect on multiple VASCUNET registries including Germany (GermanVasc), Sweden (Swedvasc), United Kingdom (UK National Vascular Registry, NVR), Australia and New Zealand (bi-national Australasian Vascular Audit), as well as the United States (Society for Vascular Surgery Vascular Quality Initiative), VQI. We will highlight the continued collaboration of VASCUNET with the VQI in the International Consortium of Vascular Registries (ICVR) as part of the Medical Device Epidemiology Network (MDEpiNet) coordinated registry network (CRN). Vascular registries must remain flexible and responsive to new and future real-world problems affecting vascular patients.

Quality improvement programs and clinical trial research experienced disruption due to the COVID-19 pandemic. Vascular registries showed an immediate impact with significant declines in second quarter vascular procedure volumes witnessed across Europe and the United States. To better understand the magnitude and impact of the pandemic, organizations and study groups sent grass roots surveys to vascular specialists for needs assessment. Several vascular registries responded quickly by insertion of COVID-19 variables into their data collection forms. Over 80% of clinical trials have been reported delayed or not started due to factors that included loss of enrollment from patient concerns or mandated institutional shutdowns, weighing the risk of trial participation on patient safety. Preliminary data of patients undergoing vascular surgery with active COVID-19 infection shows inferior outcomes (morbidity) and increased mortality. Disease specific vascular surgery study collaboratives about COVID-19 were created for the desire to study the disease in a more focused manner than possible through registry outcomes. This review describes the pandemic effect on multiple VASCUNET registries including Germany (GermanVasc), Sweden (Swedvasc), United Kingdom (UK National Vascular Registry, NVR), Australia and New Zealand (bi-national Australasian Vascular Audit), as well as the United States (Society for Vascular Surgery Vascular Quality Initiative), VQI. We will highlight the continued collaboration of VASCUNET with the VQI in the International Consortium of Vascular Registries (ICVR) as part of the Medical Device Epidemiology Network (MDEpiNet) coordinated registry network (CRN). Vascular registries must remain flexible and responsive to new and future real-world problems affecting vascular patients.

Following the global shutdown in March of 2020, quality improvement programs and clinical trial research experienced disruption due to the COVID-19 pandemic. Vascular registries showed an immediate impact with significant reductions in second quarter vascular procedure volumes witnessed across Europe and the United States. 1, 2, 3 To better understand the magnitude and impact of the pandemic, organizations and study groups sent grass roots surveys to vascular specialists for needs assessment. Several vascular registries responded quickly by insertion of COVID-19 variables into their data collection forms. Over 80% of clinical trials have been reported delayed or not started due to factors that included loss of enrollment from patient concerns or mandated institutional shutdowns, weighing the risk of trial participation on patient safety. 4 The pandemic has also spurred a rapid development of prospective patient cohort analyses, calling to attention research efforts by the Vascular and Endovascular Research Network (VERN) and the Vascular Surgery COVID-19 Collaborative (VASCC) and the challenges in 'big data'. Additionally, barriers to registry modifications and continued clinical trial research in the midst of a pandemic will be reviewed.

The severe acute respiratory syndrome SARS-CoV-2 virus responsible for the new coronavirus disease, COVID-19, infection demonstrates increased affinity for human angiotensin converting enzyme 2 receptors in respiratory epithelium through spike protein modifications, increasing transmissibility over a previous SARS-CoV outbreak in 2002. 7 Viral induced activation of coagulation pathways as well as cytokine damage to vascular endothelium secondary to COVID-19 infection provoke a prothrombotic state affecting both microvascular and macrovascular arterial and venous systems. 8 Occult strokes, venous thromboses, pulmonary thromboembolism, Kawasaki-like syndrome in children and 'COVID' toes are just some of the presentations seen from the novel coronavirus. 9,10,11

The global pandemic caused by SAR-CoV-2 virus forced the vascular community to re-assess the management of elective vascular disease while learning how to treat vascular complications of COVID-19 infection. In the absence of published literature or evidence-based data about COVID-19, vascular surgeons had to assess the risk benefit of both routine and emergency care and evaluate each in the context of local community infection rates and available hospital resources. Rapidly developed guidelines from the American College of Surgeons (Tiers 1 to 3) and the Vascular Activity Condition (VASCCON) became a useful aid for decision making triage as seen in Table 1 . 12, 13 The implications of delaying treatment for routine vascular care and the rate of progression of disease are often not well defined, although the consequences are. Delays in treatment are variable for an asymptomatic carotid stenosis versus an asymptomatic > 6.5 cm AAA or a patient with an infected dialysis catheter in need of angioacess. 14 Vascular registries are primarily procedural based and not designed to evaluate delayed care or medical management. VQI has recently released a Medical Management registry to collect data on medically managed patients with AAA, carotid stenosis, and lower extremity occlusive disease but currently has limited enrollment. Procedural registries can analyze the impact of comorbidities if the pertinent variables are in the collection form. New and unique variables must be added to the registries in order to provide data for analysis of new conditions.

The earliest insight into changes in practice patterns comes from surveys conducted on vascular surgeons. 15 A survey by Aziz et al on US vascular surgeons showed that most noticed a decrease in clinic referrals, emergency room consults and overall case volumes. 16 Similarly, a survey by the COVER study collaborative showed that globally, there was a trend in the reduction in all peripheral vascular surgery including carotid, aortic and lower extremity arterial operations. 17 These surveys also indicate that many patients with vascular disease delayed seeking medical attention and suffered adverse consequences. News media outlets reported that a number of patients with heart attack and stroke avoided emergency rooms or appropriate medical care presenting late or dying at home. Similar suppositions can be made for patients with abdominal aortic aneurysms, carotid artery stenosis and severe peripheral arterial disease. 18 Review of current literature shows that COVID-19 infection is associated with an acquired hypercoagulable state. Nypaver et al reviewed seven patients with COVID-19 who presented with stroke and concluded that COVID-19 is associated with increased thrombus formation in extracranial carotid arteries. 19 Ilonzo et al described thrombotic complications of 21 patients who were severely ill during the height of the pandemic in New York City. Overall mortality was 28.6% with over three fourths presenting with acute arterial thrombosis and critical ischemia. 20 Increased mortality in patients with COVID-19 complicated by venous thromboembolism has also been reported. 21 Patients with COVID-19 can have a myriad of presentations in vascular beds and registry databases will have to be flexible to respond rapidly to a changing clinical environment. There are important unresolved questions, such as a) when elective operations can be safely performed during a COVID-19 surge, b) which "elective" operations, e.g. >6.5 cm AAA should be prioritized in the presence of restricted resources, and c) how long does the prothrombotic condition last following COVID-19 infection before it is safe to proceed with elective operations such as treatment for claudication or varicose veins. Broadening the scope of databases to include new variables in a timely fashion will have the potential to address these important clinical dilemmas. Registry data may provide better understanding should another pandemic occur in the future.

Determining the magnitude of the novel coronavirus infection on vascular disease management requires collecting new preoperative and postoperative clinical variables. Shortly after the onset of the pandemic, VQI (regional) and VERN (international) surveyed their membership. It was evident early on that many COVID-19 risk factors are also highly prevalent in vascular surgical patients: advanced age, male gender, smoking, obesity, coronary artery disease, hypertension, chronic pulmonary disease, chronic renal disease, diabetes, malignancy, etc. Given the lack of knowledge about COVID-19, many vascular registries independently responded with rapid insertion of COVID-19 related variables into their data collection forms for monitoring impact.

Multi-center study collaboratives were formed to better understand COVID-19 impact on patients with vascular disease (VASCC and COVER [COVID- 19 Vascular Service Study]). The additional COVID-19 related variables are listed in Table 2 . As these variables were developed independently, there were some minor differences noted across registries. COVID-19 infection status, procedure delays, disease worsening and mortality were the most commonly chosen data fields. Timing of COVID-19 variable insertion into registry databases occurred as quickly as mid-April 2020 (UK NVR, Swedvasc) to early September 2020 (VQI). The speed of registry revision is remarkable given additional variable insertion typically takes a minimum of 12-18 months. The NVR COVID-19 data fields were initially added to the PAD and AAA datasets and went live in April 2020, while new variables were added to the carotid data set in June 2020. 22 The addition of COVID-19 data fields was variable in other VASCUNET registries. The GermanVasc registry retrospectively surveyed COVID-19 related variables on a voluntary basis at participating centers. The Australasian Vascular Audit has not yet elected to collect COVID-19 data. Of note, no registry or study collaborative is currently capturing data on vaccination status. This apparent oversight reflects more on the speed with which variable insertion and study collaboratives were developed prior to widespread vaccination and the burdensome nature of registry modification.

Additionally, in April of 2020, the World Health Organization (WHO) and "Family of International Classification'' (FIC) issued how a confirmed SARS-CoV-2 infection must be coded to generate reliable administrative data in the future. This has since received periodic updates as COVID-19 information has progressed. 23

As previously mentioned, most registries experienced significant initial procedural volume decline at the beginning of the pandemic, March 2020. Similar to VQI reporting, initial UK NVR analysis confirmed declines in major vascular procedures in AAA (12%), carotid endarterectomy (38%) and lower limb bypass (38%) during April of 2020. 24 By July 2020, elective volumes of AAA and CEA had returned to approximately 80% of pre-pandemic levels ( Figure 1 ). 25 Further ongoing assessment will be necessary to determine if this perception is real.

Interestingly, in Germany (which implemented extensive restrictions of public life and health services in March 2020) a decline of registry volumes and emergent admissions in administrative registries was observed, while no change in management was apparent. Elective (Asymptomatic) to Non-Elective (Symptomatic or Emergent) volume ratios for aortic and infrainguinal bypass in 2020 delined from those of 2018 and 2019 (range 8-53%, median 14%) as would be expected given the restrictions placed on elective surgeries in most countries. This resulted in a higher percentage of non-elective cases (symptomatic) overall in 2020, reflecting less elective operations. Elective/non-elective ratios for carotid and venous categories were not included in Table 3 given variable definitions and management within these categories. Differences between registries on asymptomatic carotid interventions performed in the US VQI compared to European registries has been previously reported. 26 Factors likely contributing to this reduction include patient (fear, reluctance to seek care), surgeon (change in AAA size threshold, delay in intervention), resources (bed capacity, staffing) and governance (national/state directives). 24,27 As local restrictions were lifted by July-August 2020, procedure volumes gradually approached prior annualized volumes. It remains unclear whether long term consequences will result in increased adverse patient outcomes. The pandemic provides a unique opportunity to study the natural history of medically managed AAA and symptomatic carotid stenosis. NVR reporting on emergency vascular procedures at the beginning of the pandemic showed declines in ruptured AAA (76%) and major lower limb amputation (83%). This is quite surprising as these medical catastrophes or urgent operations would not be expected to be significantly impacted. This will require further trend analysis from both registry data and study collaboratives such as VASCC and COVER.

In addition to registry data collection, COVID-19 study collaboratives seeking global cooperation and data sharing also emerged in March 2020. 17 The study was conceived as a three-tier project, each focusing on different aspects of vascular care: 1) the quantification, analysis and demonstration of changes to global vascular activity during the course of 2020, 2) in-hospital outcomes following common vascular procedures with subsequent 6 and 12month follow-up and 3) changes in the management of consecutive patients presenting with common vascular conditions during the pandemic, including medium and long term follow up. Key COVER findings documented a significant decrease in usual vascular activity, transitioning changes of care to telemedicine, and the avoidance of surgery in presentations other than only the largest aneurysms or most severe arterial occlusive disease. The study has also shown that globally, restricting treatment to more advanced clinical presentations was associated with a marked increase in-hospital overall vascular service mortality at 11% despite a modest suspected or confirmed COVID-19 infection rate (4%) 17 .

As seen in Table 2 , study collaboratives can provide a more comprehensive COVID-19 variable data collection than existing registries (which require modification) given the enhanced flexibility of creating de-novo data elements specifically targeted at COVID-19. In addition, the study collaboratives focus on the disease rather than the procedure thereby expanding the inclusion criteria for data collection.

In contrast to registries that are procedure based, study collaboratives are disease specific and focused. A patient succumbing to an adverse event (i.e. disabling stroke or ruptured aneurysm) before receiving an operation will not be included in a procedure based registry but would be included into a study collaborative given the inclusion criteria.

However, both VASCC and COVER are limited by voluntary participating centers, in contrast to population based vascular surgical registries with administrative data infrastructure. Procedure based registries and study collaboratives can monitor the effects of the pandemic on the overall vascular surgical population from different and broader perspectives. It will be important to cross link registry data (having established long term outcomes) with the robust data produced in disease specific study collaboratives to provide a more comprehensive analysis of COVID-19's pandemic effect on vascular disease management and outcomes. The US VQI has 65 centers participating in VASCC with plans to coordinate data collection and long term follow up.

Most vascular registries collect data on short-term outcome after procedures recording lengths of stay, complications and death within the primary hospitalization or 30-days from operation. Initial data from the COVER study suggests that vascular surgery in vulnerable patients may have a very high risk for mortality and morbidity. 27 Although the UK NVR COVID positive rates were only 2.2% on the vascular service (April through July 2020), mortality in AAA and PAD patients with a positive COVID-19 diagnosis was 6.1% compared to those who were negative at 2.2%. This was independent of respiratory complications defined as pneumonia, ventilator support > 48 hours, Adult Respiratory Distress Syndrome or pulmonary embolism. Mortality of COVID positive patients experiencing respiratory complications rose to 38.2% compared to those who were COVID negative at 27.9%. 24

Registries may use cross-matching of data linkage with administrative databases or other health care consortia to determine long-term survival and reintervention. Data accumulation may have a lag time of 1-2 years, thus delaying assessment of procedural outcomes until this process is complete. Use of disease specific study collaboratives and registry linkage to administrative databases will be required to understand the long-term consequences of COVID-19 infection. Table 3 indicates a variable effect of the pandemic on overall vascular surgical operation volumes during 2020 ranging from 66% to 99% compared to the previous year. The catch-up effect for vascular surgical interventions following reduced activity during a shutdown or a local viral outbreak of COVID infection will require further analysis. The downstream effect of the pandemic on more selective patient treatment or increased endovascular procedures to reduce length of hospital stay/need for intensive care also requires further detailed assessment.

The importance of scientific research during the COVID-19 pandemic has been highlighted by the dramatic advances made in both the therapeutic management of and the development of vaccines against COVID-19. Vascular surgeons recognized the importance of studying the impact of COVID-19 on vascular patients early in the pandemic and initiatives such as the VASCC and COVER are testament to this. 29 However, there is no doubt that COVID-19 has also impacted existing vascular trials. Academicians, research nurses and other research staff were frequently redeployed to support frontline hospital services at the start of the pandemic and this resulted in some important trials being halted. 30 The UK-Compass study, a multicenter study on the management of juxta-renal AAAs temporarily paused recruitment in March 2020 and restarted in July 2020. 31 The reluctance of continuing active trials or initiation of new trials by researchers, manufacturers and patients must be tempered with concern about undergoing procedures with the confounding impact of COVID-19 on outcomes (e.g. stent thrombosis or increased mortality) during the pandemic.

There has been pandemic influenced positive developments for both registries and research. VASCUNET has grown to include 26 regional and national registries in European, South American and Australasian countries who actively work together to harmonize their registry data collection and pursue collaborative research related to vascular procedures. 33 As has been demonstrated, the impact of the COVID pandemic on each registry within VASCUNET and VQI has been variable, related heavily to the overall prevalence of the virus in each country, the governmental approach to virus containment, the burden on clinical operations and the impact of personnel who collect data within each registry. Although ICVR has not yet collected harmonized variables across VASCUNET and VQI, the extensive data collection by both the VQI and numerous registries within VASCUNET will allow for future collaborative projects, similar to what has been reported previously. [34] [35] [36] Given the impact of COVID-19 on vascular practice and the high frequency of vascular complications from the virus, the value of worldwide data collection cannot be overstated. The rapid addition and harmonization of variables that has occurred during the pandemic is an exercise that will serve all ICVR participating registries in the future. Data collection for unexpected and infrequent device failures of this nature in international real-world practice will certainly benefit from the mechanisms that have been established within ICVR related to the pandemic. 37

Registry data has always played an important role in providing real world data driving clinical practice through quality improvement. It has now become increasingly evident that real world evidence (RWE) plays an important role in evaluating real world problems dynamically. In 2019, the vascular community was disrupted by the Paclitaxel controversy. Registry data helped us better understand the impact of Paclitaxel devices on long term mortality (Germanvasc, VQI, SwedePAD (trial), Australia/NZ, Spain). [38] [39] [40] [41] In 2020, the vascular community was disrupted by the COVID-19 pandemic. Again, RWE from registries is helping us better understand the impact and how we should adapt using up to date information. Undoubtedly, there will be future events or pandemics where registry data and RWE will help us to better respond in a timely manner. We must prepare our clinical and administrative registries to be adaptable, responsive and utilize active surveillance monitoring to identify signal detection or address future unknown events. As a first important step, the responsible consortia implemented corresponding codes to identify patients with positive SARS-CoV-2 infection in registry and administrative data. This emphasizes that events with enough impact can lead to changes in an often-rigid environment. The vascular community would be well advised to use the momentum noted above and discuss the implementation of unique device identifiers (UDI) into administrative data to be prepared for future tasks and challenges.

☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

Impact of COVID-19 on the Society for Vascular Surgery Vascular Quality Initiative Arterial Procedure Registry

Impact of COVID-19 on the Society for Vascular Surgery Vascular Quality Initiative Venous Procedure Registries (Varicose Vein and Inferior Vena Cava Filter)

Temporal trends in the presentation of cardiovascular and cerebrovascular emergencies during the COVID-19 pandemic in Germany -An analysis of health insurance claims

Challenges and opportunities for sponsors in conducting clinical trials during a pandemic

Impact of COVID-19 on oncology clinical trials

Impact of coronavirus disease 2019 (COVID-19) outbreak on radiology research: An Italian survey

Coronavirus: update related to the current outbreak of COVID-19

COVID-19 is, in the end, an endothelial disease

SARS-CoV-2 and limb ischemia: A systematic review

Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease

The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients

American College of Surgeons. COVID-19 guidelines for triage of vascular surgery patients. Available at: www.facs.org/covid-19/clinical-guidance/elective-case/vascularsurgery

Vascular surgery activity condition is a common language for uncommon times

The impact of the COVID-19 pandemic on vascular surgery practice in the United States

Global vascular surgeons' experience, stressors, and coping during the coronavirus disease 2019 pandemic

Implications of the severe acute respiratory syndrome associated with the novel coronavirus-2 on vascular surgery practices

VERN) COVER study collaborative. Global impact of the first coronavirus disease 2019 (COVID-19) pandemic wave on vascular services

Analysis of Outcomes in Acute Limb Ischemia Patients during COVID-19 State of Emergency in Western Massachusetts

Symptomatic Extracranial Carotid Disease in COVID-19 Patients Is Related to Thrombus Formation

Acute thrombotic manifestations of coronavirus disease 2019 infection: Experience at a large New York City health care system

Long-term follow up of patients with venous thromboembolism and COVID-19: analysis of risk factors for death and major bleeding

Vascular Society Great Britain and Ireland 27th

World Health Organization: Considerations for implementing and adjusting public health and social measures in the context of COVID-19. Interim Guidance-4

Impact of the Covid-19 pandemic on the provision of vascular surgery in the UK National Health Service. National Vascular Registry Short Report

Monitoring indirect impact of COVID-19 pandemic on services for cardiovascular diseases in the UK. Heart

Carotid Stenosis Treatment: Variation in International Practice Patterns

Outcomes of Vascular and Endovascular Interventions Performed During the Coronavirus Disease 2019 (COVID-19) Pandemic, Annals of Surgery

The Vascular Surgery COVID-19 Collaborative (VASCC)

The Need of Research Initiatives Amidst and After the Covid-19 Pandemic: A Message from the Editors of the EJVES

COVID-19 and Its Impact on the Future of Clinical Trial Execution

UK Compass: A comparison of open surgery, minimal invasive surgery and medical management for complex aortic aneurysms

Linked electronic health records for research on a nationwide cohort including over 54 million people in England. From CVD-COVID-UK Consortium

International Consortium of Vascular Registries. Variations in Abdominal Aortic Aneurysm Care: A Report From the International Consortium of Vascular Registries

Editor´s Choice -International Variations and Gender Disparities in the Treatment of Peripheral Arterial Occlusive Disease -A report from VASCUNET and the International Consortium of Vascular Registries

Hospital Volume Association With Abdominal Aortic Aneurysm Repair Mortality -Analysis of the International Consortium of Vascular Registries

Hospital Volume Association With Abdominal Aortic Aneurysm Repair Mortality -Analysis of the International Consortium of Vascular Registries

Big data in vascular surgery: registries, international collaboration and future directions

International Consortium of Vascular Registries Consensus Recommendations for Peripheral Revascularization Registry Data Collection

Long-term outcomes after revascularizations below the knee with paclitaxel-coated devices -a propensity score matched cohort analysis

Editor´s Choice -Long Term Survival After Femoropopliteal Artery Revascularizations With Paclitaxel-Coated Devices -A propensity score matched cohort analysis

Mortality After Paclitaxel Coated Balloon Angioplasty and Stenting of Superficial Femoral and Popliteal Artery in the Vascular Quality Initiative